16:58 , Mar 22, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes Patient sample and yeast studies suggest promoting ZMPSTE24 expression could help treat Type II diabetes. Whole-exome sequencing of patients and healthy volunteers identified associations between loss-of-function mutations in ZMPSTE24 and the disease. In a...
18:54 , Mar 15, 2018 |  BC Innovations  |  Product R&D

Engineered to kill

Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common...
17:42 , Mar 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; breast cancer; chronic lymphocytic leukemia (CLL); lymphoma; neuroendocrine tumors Patient sample, cell culture and mouse studies suggest inhibiting XBP1 or its activator IRE1 could help treat MYC- or MYCN-driven cancers. In breast cancer...
00:15 , Mar 10, 2018 |  BC Extra  |  Preclinical News

Increasing ZMPSTE24 could help treat, prevent Type II diabetes

A study published in Cell showed that the yeast homolog of zinc metallopeptidase STE24 (ZMPSTE24) reduced islet amyloid polypeptide (IAPP) oligomer-induced proteotoxicity by declogging aggregates found in pancreatic beta cells, suggesting that increasing ZMPSTE24 could...
21:03 , Mar 2, 2018 |  BC Week In Review  |  Financial News

Quentis debuts with $48M series A

Cancer company Quentis Therapeutics Inc. (New York, N.Y.) raised $48 million on Feb. 27 in a series A round led by existing investor Versant Ventures and new investor Polaris Partners. New investors AbbVie Ventures, Taiho...
12:37 , Feb 27, 2018 |  BC Extra  |  Financial News

Quentis debuts with $48M series A

Quentis Therapeutics Inc. (New York, N.Y.) raised $48 million in a series A round led by existing investor Versant Ventures and new investor Polaris Partners. New investors AbbVie Ventures, Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan),...
12:32 , Feb 27, 2018 |  BioCentury  |  Emerging Company Profile

Stressing out cancer

Quentis Therapeutics Inc. debuted with a $48 million series A round to develop potentially first-in-class therapies that inhibit the ER stress response, with the dual effect of killing tumor cells directly and unleashing immune cells...
17:09 , Feb 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Zika virus Mouse studies suggest inhibiting PERK or IRE1 could help prevent embryonic microcephaly caused by Zika infection. In a mouse embryo model of Zika infection, tool compound PERK or IRE1 inhibitors decreased microcephaly compared...
00:07 , Dec 22, 2017 |  BC Innovations  |  Strategy

Ovid spreads its wings

With its first two candidates for rare neurological disorders heading towards clinical proof of concept, Ovid Therapeutics Inc. is looking to capitalize on the experience it has gained to find compounds with differentiated pharmacology that...
21:24 , Nov 22, 2017 |  BC Extra  |  Preclinical News

Team identifies new gene tied to neutropenia

In an abstract released ahead of the American Society of Hematology meeting in December, a French team led by researchers at Institut Gustave-Roussy identified a new gene associated with congenital neutropenia. Whole-exome sequencing of eight patients...